We use cookies for a better user experience. Read our Privacy Policy

I Agree

Atrial Fibrillation Market

Atrial Fibrillation Market (Treatment Type: Pharmacological Treatment, Non-pharmacological Treatment, Maze Surgery, and Electric Cardioversion) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Atrial Fibrillation Market Outlook 2031

  • The global atrial fibrillation market was valued at US$ 10.2 Bn in 2021
  • The global market is projected to grow at a CAGR of 6% from 2022 to 2031
  • The global atrial fibrillation market is anticipated to exceed value of US$ 18.5 Bn by 2031

Analysts’ Viewpoint on Global Atrial Fibrillation Market Scenario

Hypertension and obesity are the leading causes of cardiovascular disorders, especially atrial fibrillation. The prevalence of these disorders is rising due to socio-economic factors such as lifestyle-induced dietary and other habits, including excessive alcohol consumption and smoking. Moreover, supporting the market growth is the rising geriatric population globally, as the risk of atrial fibrillation is higher in this group of people. Favorable results exhibited by clinical trials pertaining to combined pharmacological therapy are likely to drive the global atrial fibrillation market, by catering to the unmet medical needs prevalent in the field of atrial fibrillation. Companies are undertaking more such trials to provide better treatment option for those suffering from atrial fibrillation. The global market is also anticipated to be driven by the introduction of advanced treatment procedures such as hybrid ablation and rise in prevalence of atrial fibrillation in emerging economies of Asia.

Overview of Global Atrial Fibrillation Market

Atrial fibrillation refers to a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. Being a potentially life threatening disease and expensive to treat, the overall healthcare system views the treatment for this condition as a strategically critical area to address. Increase in global geriatric population is a key factor projected to drive the global atrial fibrillation market during the forecast period.

Request a sample to get extensive insights into the Atrial Fibrillation Market

Increase in Incidence Rate of Atrial Fibrillation Due to High Prevalence of Disorders Such as Hypertension and Obesity

Cardiovascular disorders, especially atrial fibrillation, are most times a result of hypertension and obesity. According to the Framingham Heart Study, 14% of the atrial fibrillation risks were associated with hypertension, and obesity increased the risk of progression of paroxysmal atrial fibrillation to permanent atrial fibrillation by 45% to 50%. The prevalence of these disorders is rising due to socio-economic factors such as lifestyle induced dietary and other habits (excessive alcohol consumption and smoking).

According to WHO estimates, 35% of adults aged 20 years and above were overweight. The global prevalence of obesity has almost doubled since 1980 and is expected to rapidly increase in future. Moreover, the prevalence of hypertension in 2008 was stood at 1 billion. The WHO suggests that in 2008, the prevalence of hypertension in low, middle, and upper middle income countries was 40% and 35% in high income countries. High and rise in prevalence of these disorders is expected to propel the global atrial fibrillation market during the forecast period.

Promising Results of Clinical Trials Aimed at Treating Atrial Fibrillation to Boost Market Growth

The combined pharmacological therapy is a new and promising treatment option for atrial fibrillation. The combined pharmacological therapy has exhibited encouraging results in clinical trials and would help in catering to the unmet medical needs in those suffering from atrial fibrillation. This factor is projected to drive the global atrial fibrillation market. Additionally, research results on animal mode for the combined therapy yielded favorable and synergistic anti-arrhythmic results.

The clinical trials aimed at testing the effect of a combined therapy involving Multaq and Ranexa was unveiled at the Boston Atrial Fibrillation Symposium. This clinical trial was titled HARMONY and enrolled around 150 patients with non-permanent atrial fibrillation and with implanted pacemakers. Preclinical data revealed by this study suggest that this combination therapy is well positioned in the current anti-arrhythmic drugs segment, especially on the grounds of safety and efficacy.

Request a custom report on Atrial Fibrillation Market

Stringent FDA, CE, and European Medicines Agency Product Approval Regulations to Hamper Market

Atrial fibrillation devices such as implantable pacemakers, defibrillators, and catheters are regarded as class III high risk medical devices by the U.S. FDA. Therefore, these devices undergo rigorous safety and efficacy tests prior to receiving an approval. Moreover, these devices need to obtain a premarket approval, which is an expensive and lengthy affair. Atrial fibrillation drugs are no exception to these stringent regulations and hence, need to undergo strictly monitored safety and efficacy tests. Failure to comply with the regulations laid down by the FDA and European Medicines Agency will result in a product recall or clinical trial termination. For instance, termination of PALLAS study and issuance of safety alerts by the FDA for Multaq.

Increase in Geriatric Population to Drive Global Market

Surge in global geriatric population increases the incidence rate of atrial fibrillation. This acts as a major driver for the global atrial fibrillation market. Additionally, favorable results exhibited by clinical trials promoting combined pharmacological therapy such as the HARMONY trial and rise in prevalence of disorders causing atrial fibrillation such as hypertension and obesity are projected to propel the global atrial fibrillation market.

Pharmacological Treatment Segment to Dominate Global Market

In terms of product type, the global atrial fibrillation market has been bifurcated into pharmacological treatment and non-pharmacological treatment. The pharmacological treatment segment accounted for a leading share of the global market in 2021. The pharmacological treatment procedures are administered more frequently to patients suffering from atrial fibrillation, and are a cheaper alternative to non-pharmacological procedures. The pharmacological treatment procedures segment is expected to gain market share due to the introduction of new drugs such as Bristol Myer Squibb’s NTC-801, Merck’s Vernakalant, and Boehringer Ingelheim’s Pradaxa.

Regional Outlook of Global Atrial Fibrillation Market

In terms of region, the global atrial fibrillation market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global atrial fibrillation market in 2021, followed by Europe.

North America is a leading market for atrial fibrillation due to high prevalence of atrial fibrillation, high disposable income of patients, and sophisticated healthcare infrastructure. Emerging markets in Asia Pacific exhibit immense growth potential due to initiatives taken by governments to promote healthcare and robust economic growth. Moreover, improving purchasing power, consumer awareness about health issues, and better disease management are likely to fuel the growth of the atrial fibrillation market in Asia Pacific.

Analysis of Key Players in Global Atrial Fibrillation Market

This report profiles key players in the global atrial fibrillation market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global atrial fibrillation market is highly fragmented, with the presence of a number of international as well as regional players. Leading players operating in the global atrial fibrillation market are AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, St. Jude Medical, Inc., and Johnson & Johnson Ltd, among others.

Key Developments in Global Atrial Fibrillation Market

Key players in the global atrial fibrillation market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global atrial fibrillation market. A few expansion strategies adopted by players operating in the global atrial fibrillation market are:

  • In January 2022, Voluntis, an Aptar Pharma company and leader in digital therapeutics has entered into a partnership agreement with AliveCor, Inc. for Advance Management of Atrial Fibrillation for Patients with Cancer
  • In July 2021, AliveCor, Inc. and Acutus Medical have announced a partnership to evaluate the integration of data collection tools across the cardiology continuum of care, with the goal of improving arrhythmia treatment and disease management
  • In May 2020, CardioFocus, Inc. announced that it has received the U.S. Food & Drug administration approval for its next-generation HearLight X3 Endoscopic Ablation System. The system can be used for the drug refractory recurrent symptomatic paroxysmal atrial fibrillation treatment.
  • In September 2019, iRhythm Technologies, Inc. announced a collaboration with Verily, an Alphabet company, to develop solutions to improve the screening, diagnosis, and management of atrial fibrillation patients (AFib)

Global Atrial Fibrillation Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 10.2 Bn

Market Forecast Value in 2031

US$ 18.5 Bn

Growth Rate (CAGR)

6%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Treatment Type
    • Pharmacological Treatment
      • Anti-arrhythmic Drugs
      • Anti-coagulant Drugs
    • Non-pharmacological Treatment
      • Catheter Ablation
        • Radiofrequency Based
        • Cryoablation Based
        • HIFU (High Intensity Focused Ultrasound) Based
        • Microwave Based
        • Laser Based
    • Maze Surgery
    • Electric Cardioversion

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • AtriCure, Inc.
  • Biosense Webster, Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • CardioFocus, Inc.
  • Endoscopic Technologies, Inc.
  • Sanofi Aventis
  • St. Jude Medical, Inc.
  • Johnson and Johnson Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global atrial fibrillation market in 2021?

The global atrial fibrillation market was valued at US$ 10.2 Bn in 2021.

How big will be the atrial fibrillation market in 2031?

The global atrial fibrillation market is expected to surpass US$ 18.5 Bn by 2031.

What is the CAGR of global atrial fibrillation market during the forecast period (2022-2031)?

The global atrial fibrillation market is anticipated to record a CAGR of 6% from 2022 to 2031.

What are the prominent trends impacting market growth?

Increase in incidence of atrial fibrillation due to rise in prevalence of disorders such as hypertension and obesity positively impact the global market

What is the market share of leading segment in the global atrial fibrillation market?

The pharmacological treatment segment held over 54% share of the global atrial fibrillation market in 2021.

Which region held the key market share during the forecast period?

North America is expected to be a potential revenue generator for vendors during the forecast period.

Who are the prominent players in global atrial fibrillation market?

Prominent players in the global atrial fibrillation market include AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, St. Jude Medical, Inc. and Johnson and Johnson Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Atrial Fibrillation Market

4. Market Overview

    4.1. Introduction

        4.1.1. Treatment Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Atrial Fibrillation Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Industry Developments

    5.2. Disease Prevalence & Incidence Rate, by Region/Globally

    5.3. Atrial Fibrillation Overview

    5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

6. Global Atrial Fibrillation Market Analysis and Forecast, by Treatment Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment Type, 2017–2031

        6.3.1. Pharmacological Treatment

            6.3.1.1. Anti-arrhythmic Drugs

            6.3.1.2. Anti-coagulant Drugs

        6.3.2. Non-pharmacological Treatment

            6.3.2.1. Catheter Ablation

                6.3.2.1.1. Radiofrequency Based

                6.3.2.1.2. Cryoablation Based

                6.3.2.1.3. HIFU (High Intensity Focused Ultrasound) Based

                6.3.2.1.4. Microwave Based

                6.3.2.1.5. Laser Based

            6.3.2.2. Maze Surgery

            6.3.2.3. Electric Cardioversion

    6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Atrial Fibrillation Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Market Value Forecast, by Region

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness Analysis, by Region

8. North America Atrial Fibrillation Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. Market Value Forecast, by Treatment Type, 2017–2031

        8.2.1. Pharmacological Treatment

            8.2.1.1. Anti-arrhythmic Drugs

            8.2.1.2. Anti-coagulant Drugs

        8.2.2. Non-pharmacological Treatment

            8.2.2.1. Catheter Ablation

                8.2.2.1.1. Radiofrequency Based

                8.2.2.1.2. Cryoablation Based

                8.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based

                8.2.2.1.4. Microwave Based

                8.2.2.1.5. Laser Based

            8.2.2.2. Maze Surgery

            8.2.2.3. Electric Cardioversion

    8.3. Market Value Forecast, by Country, 2017–2031

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis

        8.4.1. By Treatment Type

        8.4.2. By Country

9. Europe  Atrial Fibrillation Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Treatment Type, 2017–2031

        9.2.1. Pharmacological Treatment

            9.2.1.1. Anti-arrhythmic Drugs

            9.2.1.2. Anti-coagulant Drugs

        9.2.2. Non-pharmacological Treatment

            9.2.2.1. Catheter Ablation

                9.2.2.1.1. Radiofrequency Based

                9.2.2.1.2. Cryoablation Based

                9.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based

                9.2.2.1.4. Microwave Based

                9.2.2.1.5. Laser Based

            9.2.2.2. Maze Surgery

            9.2.2.3. Electric Cardioversion

    9.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Italy

        9.3.5. Spain

        9.3.6. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Treatment Type

        9.4.2. By Country/Sub-region

10. Asia Pacific Atrial Fibrillation Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment Type, 2017–2031

        10.2.1. Pharmacological Treatment

            10.2.1.1. Anti-arrhythmic Drugs

            10.2.1.2. Anti-coagulant Drugs

        10.2.2. Non-pharmacological Treatment

            10.2.2.1. Catheter Ablation

                10.2.2.1.1. Radiofrequency Based

                10.2.2.1.2. Cryoablation Based

                10.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based

                10.2.2.1.4. Microwave Based

                10.2.2.1.5. Laser Based

            10.2.2.2. Maze Surgery

            10.2.2.3. Electric Cardioversion

    10.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        10.3.1. China

        10.3.2. Japan

        10.3.3. India

        10.3.4. Australia & New Zealand

        10.3.5. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Treatment Type

        10.4.2. By Country/Sub-region

11. Latin America  Atrial Fibrillation Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment Type, 2017–2031

        11.2.1. Pharmacological Treatment

            11.2.1.1. Anti-arrhythmic Drugs

            11.2.1.2. Anti-coagulant Drugs

        11.2.2. Non-pharmacological Treatment

            11.2.2.1. Catheter Ablation

                11.2.2.1.1. Radiofrequency Based

                11.2.2.1.2. Cryoablation Based

                11.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based

                11.2.2.1.4. Microwave Based

                11.2.2.1.5. Laser Based

            11.2.2.2. Maze Surgery

            11.2.2.3. Electric Cardioversion

    11.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Treatment Type

        11.4.2. By Country/Sub-region

12. Middle East & Africa  Atrial Fibrillation Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment Type, 2017–2031

        12.2.1. Pharmacological Treatment

            12.2.1.1. Anti-arrhythmic Drugs

            12.2.1.2. Anti-coagulant Drugs

        12.2.2. Non-pharmacological Treatment

            12.2.2.1. Catheter Ablation

                12.2.2.1.1. Radiofrequency Based

                12.2.2.1.2. Cryoablation Based

                12.2.2.1.3. HIFU (High Intensity Focused Ultrasound) Based

                12.2.2.1.4. Microwave Based

                12.2.2.1.5. Laser Based

            12.2.2.2. Maze Surgery

            12.2.2.3. Electric Cardioversion

    12.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Treatment Type

        12.4.2. By Country/Sub-region

13. Competition Landscape

    13.1. Market Player - Competition Matrix (by tier and size of companies)

    13.2. Company Profiles

        13.2.1. Agilent Technologies, Inc.

            13.2.1.1. Company Overview

            13.2.1.2. Business Overview

            13.2.1.3. Financial Overview

            13.2.1.4. SWOT Analysis

            13.2.1.5. Strategic Overview

        13.2.2. Allied Healthcare Products, Inc.

            13.2.2.1. Company Overview

            13.2.2.2. Business Overview

            13.2.2.3. Financial Overview

            13.2.2.4. SWOT Analysis

            13.2.2.5. Strategic Overview

        13.2.3. CareFusion Corporation

            13.2.3.1. Company Overview

            13.2.3.2. Business Overview

            13.2.3.3. Financial Overview

            13.2.3.4. SWOT Analysis

            13.2.3.5. Strategic Overview

        13.2.4. Covidien plc

            13.2.4.1. Company Overview

            13.2.4.2. Business Overview

            13.2.4.3. Financial Overview

            13.2.4.4. SWOT Analysis

            13.2.4.5. Strategic Overview

        13.2.5. GE Healthcare Ltd.

            13.2.5.1. Company Overview

            13.2.5.2. Business Overview

            13.2.5.3. Financial Overview

            13.2.5.4. SWOT Analysis

            13.2.5.5. Strategic Overview

        13.2.6. GF Health Products, Inc.

            13.2.6.1. Company Overview

            13.2.6.2. Business Overview

            13.2.6.3. Financial Overview

            13.2.6.4. SWOT Analysis

            13.2.6.5. Strategic Overview

        13.2.7. Omron Healthcare, Inc.

            13.2.7.1. Company Overview

            13.2.7.2. Business Overview

            13.2.7.3. Financial Overview

            13.2.7.4. SWOT Analysis

            13.2.7.5. Strategic Overview

        13.2.8. PARI Respiratory Equipment, Inc.

            13.2.8.1. Company Overview

            13.2.8.2. Business Overview

            13.2.8.3. Financial Overview

            13.2.8.4. SWOT Analysis

            13.2.8.5. Strategic Overview

        13.2.9. Philips Healthcare

            13.2.9.1. Company Overview

            13.2.9.2. Business Overview

            13.2.9.3. Financial Overview

            13.2.9.4. SWOT Analysis

            13.2.9.5. Strategic Overview

List of Table

Table 1: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, 2017–2031

Table 2: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology, 2017–2031 

Table 3: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 4: North America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031

Table 5: North America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 6: Europe Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031

Table 7: Europe Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 8: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031

Table 9: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Latin America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031

Table 11: Latin America Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) Forecast, by Technology Type, 2017–2031

Table 13: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

List of Figure

Figure 1: Global Atrial Fibrillation Market Size (US$ Mn) Forecast, 2017–2031

Figure 2: Global Atrial Fibrillation Market Value Share, by Treatment Type, 2021

Figure 3: Global Atrial Fibrillation Market Value Share, by Region, 2021

Figure 4: Global Molecular Diagnostic Market Attractiveness Analysis, by Treatment Type, 2021

Figure 5: Global Pharmacological Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2031

Figure 6: Global Non-pharmacological Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2031

Figure 7: Global Atrial Fibrillation Market Attractiveness Analysis, by Region, 2022–2031

Figure 8: North America Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 9: North America Atrial Fibrillation Market Attractiveness Analysis, by Country, 2022–2031

Figure 10: North America Market Value Share Analysis, by Technology Type, 2017 and 2031

Figure 11: North America Market Attractiveness Analysis, by Technology Type, 2022 and 2031

Figure 12: North America Market Value Share Analysis, by Country, 2017 and 2031

Figure 13: North America Market Attractiveness Analysis, by Technology, 2022–2031

Figure 14: Europe Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 15: Europe Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 16: Europe Market Value Share Analysis, by Technology Type, 2017 and 2031

Figure 17: Europe Market Attractiveness Analysis, by Technology Type, 2017 and 2031

Figure 18: Europe Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 19: Europe Market Attractiveness Analysis, by Technology, 2022–2031

Figure 20: Asia Pacific Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 21: Asia Pacific Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 22: Asia Pacific Market Value Share Analysis, by Technology Type, 2017 and 2031

Figure 23: Asia Pacific Market Attractiveness Analysis, by Technology Type, 2017 and 2031

Figure 24: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 25: Asia Pacific Market Attractiveness Analysis, by Technology, 2022–2031

Figure 26: Latin America Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 27: Latin America Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 28: Latin America Market Value Share Analysis, by Technology Type, 2017 and 2031

Figure 29: Latin America Market Attractiveness Analysis, by Technology Type, 2017 and 2031

Figure 30: Latin America Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 31: Latin America Market Attractiveness Analysis, by Technology, 2022–2031

Figure 32: Middle East & Africa Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 33: Middle East & Africa Atrial Fibrillation Market Attractiveness Analysis, by Country/Sub-region, 2020

Figure 34: Middle East & Africa Market Value Share Analysis, by Technology Type, 2017 and 2031

Figure 35: Middle East & Africa Market Attractiveness Analysis, by Technology Type, 2017 and 2031

Figure 36: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 37: Middle East & Africa Market Attractiveness Analysis, by Technology, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

924

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved